Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its first quarter 2018 financial results after the close of market on Tuesday, May 1, 2018 . Following the announcement, Veracyte will host a conference call and webcast
View HTML
Toggle Summary Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma ® Xpression Atlas platform to
View HTML
Toggle Summary Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018
RNA Sequencing-Based Platform Will Provide Extensive Genomic Content to Help Inform Surgery and Treatment Decisions for Patients with Suspected Thyroid Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that its soon-to-be-launched
View HTML
Toggle Summary Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society , suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma GSC To Be Presented at ENDO 2018
Company to Unveil New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 14, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data will be presented at ENDO 2018, the annual meeting of the Endocrine Society , underscoring the ability of the Afirma
View HTML
Toggle Summary Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook
Full-Year Revenue Grew 11%, to $72.0 Million Announces Upcoming Launch of Afirma Xpression Atlas Platform Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results and business
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 12, 2018-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its fourth quarter and full-year 2017 financial results after the close of market on Tuesday, February 27, 2018 . Following the announcement, Veracyte will host a
View HTML
Toggle Summary Veracyte to Present at LEERINK Partners 7th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 31, 2018-- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the LEERINK Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 2:00 p.m.
View HTML
Toggle Summary Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
Milestone Comes During National Thyroid Awareness Month SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 25, 2018-- During National Thyroid Awareness Month in January, Veracyte, Inc. (NASDAQ: VCYT) announced that to date it has performed 100,000 Afirma genomic tests to help reduce unnecessary
View HTML
Toggle Summary Veracyte's Chief Science and Medical Officer to Present at The Precision Medicine World Conference
Dr. Giulia Kennedy will highlight company's successful use of machine learning to develop genomic diagnostic tests SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced that Giulia C. Kennedy , Ph.D., chief science and medical officer, will present at the Precision
View HTML